CX3CR1 and metastatic melanoma: To this end, we evaluated surgically resected non-lymphoid primary or metastatic melanoma from seven patients using flow cytometry (Supplementary Fig. S2) and found that approximately 11% (range 1.8%–19.8%) of CD8+ TILs expressed CX3CR1 (Fig. 1A).